A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19
A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19
The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to clinical status assessed by a 7-point ordinal scale on Day 14.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Anaheim, California 92806, United States
Downey, California 90241, United States
Fontana, California 92335, United States
Harbor City, California 90710, United States
Los Angeles, California 90034, United States
Los Angeles, California 91365, United States
Moreno Valley, California 92555, United States
Ontario, California 91761, United States
Orange, California 92868, United States
Panorama City, California 91402, United States
Riverside, California 92505, United States
San Diego, California 92120-2507, United States
San Diego, California 92123, United States
San Francisco, California 94080, United States
San Francisco, California 94109, United States
San Francisco, California 94115, United States
San Jose, California 95119, United States
San Leandro, California 94577, United States
Santa Clara, California 95051, United States
Ann Arbor, Michigan 48109-5378, United States
Missoula, Montana 59802, United States
New Brunswick, New Jersey 08901, United States
Newark, New Jersey 07112, United States
New York, New York 10003, United States
New York, New York 10032, United States
Philadelphia, Pennsylvania 19104, United States
Dallas, Texas 75390, United States
Dallas, Texas 75390, United States
Montpelier Cedex 5, 34295, France
Berlin, 13353, Germany
Düsseldorf, 40225, Germany
Leipzig, 4129, Germany
Munich, 81675, Germany
Stuttgart, 70376, Germany
Milan, 20157, Italy
Padova PD, 35121, Italy
Roma, 00149, Italy
Bizkaia, 48903, Spain